Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

SRRK

Scholar Rock Holding Corp

Feb 13 • 04:00PM ET

45.98

-0.68 -1.46 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN NBIX SRPT BMRN RARE FOLD IONS BLUE TVRD

| Held by: VTI XBI IWM VXF IWO IBB SCHA VTWO VHT ITOT

Index	RUT	P/E	-	EPS (ttm)	-3.25	Insider Own	21.78%	Shs Outstand	99.17M	Perf Week	-3.44%
Market Cap	4.69B	Forward P/E	-	EPS next Y	-3.05	Insider Trans	0.98%	Shs Float	79.79M	Perf Month	0.88%
Enterprise Value	4.43B	PEG	-	EPS next Q	-0.89	Inst Own	105.26%	Short Float	19.47%	Perf Quarter	49.19%
Income	-353.43M	P/S	-	EPS this Y	-39.13%	Inst Trans	6.27%	Short Ratio	11.30	Perf Half Y	42.40%
Sales	0.00M	P/B	18.61	EPS next Y	11.10%	ROA	-119.63%	Short Interest	15.53M	Perf YTD	4.38%
Book/sh	2.47	P/C	12.69	EPS next 5Y	11.84%	ROE	-218.04%	52W High	49.82 -7.71%	Perf Year	22.19%
Cash/sh	3.62	P/FCF	-	EPS past 3/5Y	11.76% -5.90%	ROIC	-101.05%	52W Low	22.71 102.47%	Perf 3Y	359.80%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	3.92% 5.15%	Perf 5Y	-15.54%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-31.71%	Oper. Margin	-	ATR (14)	2.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.30	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.44	Recom	1.06
Dividend Gr. 3/5Y	- -	Current Ratio	6.30	EPS Q/Q	-35.28%	SMA20	0.20%	Beta	0.70	Target Price	50.36
Payout	-	Debt/Eq	0.45	Sales Q/Q	-	SMA50	2.16%	Rel Volume	0.55	Prev Close	46.66
Employees	196	LT Debt/Eq	0.43	Earnings	Nov 14 BMO	SMA200	25.29%	Avg Volume	1.37M	Price	45.98
IPO	May 24, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.85% -100.00%	Trades		Volume	752,179	Change	-1.46%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-09-26	Initiated	Citigroup	Buy	$55
Nov-18-25	Initiated	Wolfe Research	Outperform	$42
Oct-09-25	Initiated	BofA Securities	Buy	$53
Sep-17-25	Initiated	Barclays	Overweight	$45
Sep-15-25	Initiated	Leerink Partners	Outperform	$51
Aug-21-25	Resumed	Jefferies	Buy	$50
Jul-30-25	Resumed	Raymond James	Strong Buy	$53
Jul-17-25	Initiated	Cantor Fitzgerald	Overweight
Nov-26-24	Reiterated	H.C. Wainwright	Buy	$40 → $50
Oct-07-24	Reiterated	H.C. Wainwright	Buy	$30 → $35
Mar-28-24	Initiated	Raymond James	Strong Buy	$30
Oct-25-23	Upgrade	Jefferies	Hold → Buy	$20
Apr-03-23	Resumed	Piper Sandler	Overweight	$26
Sep-19-22	Resumed	H.C. Wainwright	Buy	$30
Jul-12-22	Initiated	Truist	Buy	$20
Mar-23-22	Initiated	H.C. Wainwright	Buy	$24
Dec-22-21	Downgrade	Jefferies	Buy → Hold	$52 → $28
Nov-19-21	Initiated	Piper Sandler	Overweight	$56
Apr-26-21	Resumed	Credit Suisse	Outperform	$65
Jan-11-21	Initiated	Credit Suisse	Outperform	$65

Show Previous Ratings

Feb-13-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-10-26 08:00AM	Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 (Business Wire)
Jan-16-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-12-26 07:00AM	Scholar Rock Highlights 2026 Strategic Priorities (Business Wire)
Jan-05-26 08:00AM	Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
10:57AM	Loading…
Dec-13-25 10:57AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-25 08:00AM	Scholar Rock to Present at Upcoming Investor Conferences (Business Wire) +9.14%
Nov-16-25 11:16AM	Scholar Rock (SRRK) Soars 29% as Drug Candidate Progresses (Insider Monkey)
Nov-15-25 07:07AM	Scholar Rock (SRRK) Climbs 24% on Drug Candidate Progress (Insider Monkey)
Nov-14-25 02:02PM	Scholar Rock Holding Corp (SRRK) Q3 2025 Earnings Call Highlights: Strategic Moves and ... (GuruFocus.com) +24.41%
07:00AM	Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
Nov-12-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:15AM	3 Beaten-Down Stocks With Rebound Potential This Earnings Season (MarketBeat)
Nov-04-25 08:00AM	Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference (Business Wire)
Oct-23-25 08:00AM	Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025 (Business Wire)
06:15PM	Loading…
Oct-17-25 06:15PM	Dayforce, Scholar Rock, and More Stocks See Action From Activist Investors (Barrons.com) -5.10%
04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Oct-13-25 05:22PM	Why Scholar Rock Stock Got Socked on Monday (Motley Fool) -13.14% -6.93%
Oct-09-25 05:07PM	Why Scholar Rock Stock Raced 6% Higher Today (Motley Fool) +5.94%
Oct-08-25 01:10PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-23-25 04:06PM	Scholar Rock, A Top 10% Stock, Reverses Higher Despite A Surprise Setback (Investor's Business Daily)
10:04AM	Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug (Investor's Business Daily)
07:11AM	US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall (Reuters)
07:00AM	FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility (Business Wire)
06:19AM	Scholar Rock SMA drug rejected by FDA over manufacturing concerns (BioPharma Dive)
Sep-15-25 04:54PM	Why Scholar Rock Stock Bounced Higher on Monday (Motley Fool) +6.32%
Sep-12-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 03:31AM	Can Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger? (Insider Monkey)
Aug-21-25 12:18PM	Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD (Insider Monkey)
04:15PM	Loading…
Aug-15-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:20AM	Veru Announces Novel Modified-Release Oral Formulation for Enobosarm (Zacks)
Aug-14-25 08:00AM	Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment (Business Wire)
Aug-11-25 08:21PM	Scholar Rock's Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss (Insider Monkey)
Aug-06-25 05:10PM	Why Scholar Rock Stock Wilted on Wednesday (Motley Fool) -6.40% -9.30%
07:00AM	Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
Jul-21-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 (Business Wire)
Jul-18-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-23-25 08:00AM	Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial (Business Wire)
Jun-20-25 03:45PM	Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says (Reuters) -6.28%
Jun-19-25 02:01PM	Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial (Insider Monkey)
Jun-18-25 01:41PM	Why Scholar Rock Shares Are Soaring Today (Motley Fool) +16.60%
11:40AM	Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results (Investopedia)
07:42AM	Scholar Rock drug preserves muscle in obesity trial (BioPharma Dive)
07:00AM	Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss (Business Wire)
Jun-13-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 08:00AM	Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (Business Wire) +11.13%
Jun-02-25 08:00AM	Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager (Business Wire)
May-28-25 08:00AM	Scholar Rock to Present at the Jefferies Global Healthcare Conference (Business Wire) -5.28%
May-16-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-15-25 03:10AM	Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings Call Highlights: Strong Progress and ... (GuruFocus.com)
01:39AM	Q1 2025 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-25 07:00AM	Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
May-13-25 09:24AM	What To Expect From Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings (GuruFocus.com)
May-07-25 08:00AM	Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025 (Business Wire)
May-06-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.01%
Apr-28-25 07:08PM	Why Scholar Rock Stock Took a Knock on Monday (Motley Fool)
06:50AM	Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth (Business Wire)
Apr-23-25 06:34PM	Why Scholar Rock Holding Stock Topped the Market Today (Motley Fool) +5.72%
Apr-21-25 04:37PM	Scholar Rock Holding Corp (SRRK) Q4 2024 Earnings Call Highlights: Clinical Success and ... (GuruFocus.com) +6.14%
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-18-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-17-25 11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-25-25 07:30AM	FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy (Business Wire)
Mar-17-25 08:31AM	Scholar Rock SMA drug shows muscle function benefit (Clinical Trials Arena)
Mar-16-25 07:00PM	Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire)
Mar-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 11:16PM	Q4 2024 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents) +7.95%
07:00AM	Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress (Business Wire)
Feb-26-25 07:24AM	Earnings To Watch: Scholar Rock Holding Corp (SRRK) Reports Q4 2024 Result (GuruFocus.com)
Feb-25-25 04:15PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire)
Feb-24-25 01:10PM	Is Scholar Rock Holding (SRRK) One of the Oversold Biotech Stocks to Buy Now? (Insider Monkey)
Feb-21-25 08:00AM	Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (Business Wire)
Feb-14-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-10-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025 (Business Wire)
Jan-29-25 08:05AM	Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) (Business Wire)
08:00AM	Scholar Rock Announces the Appointment of Industry Leader Lisa Wyman as Chief Technical and Quality Officer and Planned Leadership Transition (Business Wire)
Jan-17-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-13-25 06:48PM	Heres Why Scholar Rock Holding Corporation (SRRK) Is Skyrocketing (Insider Monkey) +5.21%
Jan-08-25 04:00PM	Scholar Rock Highlights 2025 Strategic Priorities (Business Wire)
Jan-02-25 08:00AM	Scholar Rock to Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-04-24 12:36PM	Why Is Scholar Rock Holding Corporation (SRRK) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga) +26.07%
06:13AM	Biohaven muscle drug misses goal of SMA study, but advances in obesity (BioPharma Dive)
Nov-15-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-24 02:08AM	Scholar Rock Holding Corp (SRRK) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-12-24 07:00AM	Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business Progress (Business Wire) -5.29%
Nov-11-24 07:07AM	Scholar Rock Holding Corp (SRRK) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-04-24 08:00AM	Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with Metformin (Business Wire)
Nov-01-24 08:00AM	Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (Business Wire)
Oct-31-24 04:00PM	Scholar Rock to Participate in Upcoming Investor Conferences (Business Wire) -5.14%
08:00AM	Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual Meeting (Business Wire)
Oct-22-24 08:00AM	Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public Offering (Business Wire)
Oct-21-24 09:55AM	Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross? (Zacks)
Oct-18-24 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-11-24 06:30PM	PBF Energy, Gold Reserve, and More Stocks See Action From Activist Investors (Barrons.com) +7.58%
Oct-09-24 05:34PM	Scholar Rock Holding Corp (SRRK) Q2 2024 Earnings Call Highlights: Advancing Key Milestones in ... (GuruFocus.com) -5.83% -5.87%

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 22 '26	Sale	46.71	14,898	695,938	85,660	Jan 23 04:30 PM
Mohammed Qatanani	Officer	Jan 22 '26	Proposed Sale	46.05	14,898	686,053		Jan 22 04:14 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 16 '26	Sale	44.48	8,406	373,880	100,558	Jan 21 07:52 PM
Parlavecchio Caryn	CHRO	Jan 16 '26	Sale	44.48	6,600	293,553	148,864	Jan 21 07:51 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Jan 16 '26	Sale	44.48	5,798	257,882	95,687	Jan 21 07:50 PM
Ho Junlin	GENERAL COUNSEL	Jan 16 '26	Sale	44.48	8,016	356,533	214,553	Jan 21 07:50 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 14 '26	Option Exercise	18.53	13,112	242,961	122,076	Jan 16 06:37 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 14 '26	Sale	45.20	13,112	592,611	108,964	Jan 16 06:37 PM
Sinha Vikas	Chief Financial Officer	Jan 13 '26	Sale	42.70	16,755	715,438	583,245	Jan 15 07:58 PM
Woods Keith	Chief Operating Officer	Jan 13 '26	Sale	42.70	16,746	715,054	583,254	Jan 15 07:57 PM
Vaishnaw Akshay	President of R&D	Jan 13 '26	Sale	42.70	20,438	872,703	595,767	Jan 15 07:56 PM
Hallal David	Chief Executive Officer	Jan 13 '26	Sale	42.70	57,450	2,453,115	1,541,645	Jan 15 07:54 PM
Peng Katie	Director	Dec 16 '25	Sale	44.09	1,006	44,352	32,908	Dec 18 04:30 PM
AKKARAJU SRINIVAS	Director	Oct 07 '25	Buy	39.92	29,599	1,181,634	530,038	Dec 16 09:07 PM
Katie Peng	Director	Dec 16 '25	Proposed Sale	45.24	1,006	45,511		Dec 16 06:02 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Dec 04 '25	Option Exercise	21.21	136,462	2,894,077	245,426	Dec 05 04:53 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Dec 04 '25	Sale	45.21	136,462	6,169,788	108,964	Dec 05 04:53 PM
Mohammed Qatanani	Officer	Dec 04 '25	Proposed Sale	43.01	149,574	6,433,178		Dec 04 04:19 PM
AKKARAJU SRINIVAS	Director	Oct 03 '25	Buy	37.27	387,414	14,438,544	387,414	Oct 07 08:59 PM
AKKARAJU SRINIVAS	Director	Oct 06 '25	Buy	38.65	113,025	4,368,808	500,439	Oct 07 08:59 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 22 '25	Sale	30.67	3,353	102,846	108,964	Sep 24 04:30 PM
Mohammed Qatanani	Officer	Sep 22 '25	Proposed Sale	30.67	3,353	102,846		Sep 22 04:33 PM
Peng Katie	Director	Sep 16 '25	Sale	32.53	1,006	32,726	33,914	Sep 17 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Sep 16 '25	Sale	33.52	3,178	106,527	112,317	Sep 17 04:30 PM
Katie Peng	Director	Sep 16 '25	Proposed Sale	32.53	1,006	32,726		Sep 16 04:32 PM
Parlavecchio Caryn	CHRO	Aug 18 '25	Sale	31.17	2,178	67,880	155,464	Aug 19 04:30 PM
FLIER JEFFREY S.	Director	Jul 16 '25	Sale	40.02	11,136	445,688	0	Jul 18 04:15 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jul 08 '25	Sale	34.44	24,066	828,898	115,495	Jul 10 09:46 PM
Mohammed Qatanani	Officer	Jul 08 '25	Proposed Sale	35.48	24,066	853,862		Jul 08 04:12 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Option Exercise	21.62	20,316	439,232	44,386	Jun 25 04:30 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Sale	32.24	20,316	654,904	24,070	Jun 25 04:30 PM
FLIER JEFFREY S.	Director	Jun 23 '25	Sale	33.21	11,136	369,818	11,136	Jun 25 04:30 PM
Peng Katie	Director	Jun 16 '25	Sale	31.97	3,031	96,888	34,920	Jun 17 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jun 16 '25	Sale	32.00	3,668	117,381	139,561	Jun 17 04:30 PM
Parlavecchio Caryn	CHRO	Jun 16 '25	Sale	32.00	6,186	197,961	157,642	Jun 17 04:30 PM
Ho Junlin	GENERAL COUNSEL	Jun 16 '25	Sale	32.00	7,442	238,154	222,569	Jun 17 04:30 PM
Edward Myles	Former Officer	Jun 05 '25	Proposed Sale	32.50	19,599	636,967		Jun 05 04:57 PM
FLIER JEFFREY S.	Director	May 29 '25	Sale	29.73	6,075	180,584	24,070	May 30 04:32 PM
Burow Kristina	Director	May 29 '25	Sale	29.72	5,400	160,511	21,071	May 30 04:31 PM
Gilman Michael	Director	May 29 '25	Sale	29.72	3,375	100,304	55,216	May 30 04:31 PM
Brudnick Richard	Director	May 29 '25	Sale	29.72	6,075	180,531	15,057	May 30 04:31 PM
Reed Joshua	Director	May 29 '25	Sale	29.72	5,400	160,463	15,732	May 30 04:30 PM
Vaishnaw Akshay	President of R&D	May 29 '25	Sale	29.72	6,750	200,612	616,205	May 30 04:30 PM
Akshay Vaishnaw	Director	May 29 '25	Proposed Sale	29.66	6,750	200,205		May 29 04:51 PM
Joshua Reed	Director	May 29 '25	Proposed Sale	29.66	5,400	160,164		May 29 04:49 PM
Michael Gilman	Director	May 29 '25	Proposed Sale	29.66	3,375	100,103		May 29 04:46 PM
Jeffrey S. Flier	Director	May 29 '25	Proposed Sale	29.66	48,663	1,443,345		May 29 04:43 PM
Kristina Burow	Director	May 29 '25	Proposed Sale	29.66	5,400	160,164		May 29 04:39 PM
Richard Brudnick	Director	May 29 '25	Proposed Sale	29.66	6,075	180,185		May 29 04:35 PM
Sacco Tracey	Chief Commercial Officer	Apr 25 '25	Option Exercise	10.00	5,000	50,000	76,250	Apr 29 06:03 PM
Sacco Tracey	Chief Commercial Officer	Apr 25 '25	Sale	32.83	5,000	164,131	71,750	Apr 29 06:03 PM
Sacco Tracey	Chief Commercial Officer	Mar 24 '25	Option Exercise	10.00	5,000	50,000	78,250	Mar 25 07:39 PM
Sacco Tracey	Chief Commercial Officer	Mar 24 '25	Sale	33.08	6,500	215,014	71,750	Mar 25 07:39 PM
Moore Erin	Interim PFO and PAO	Mar 24 '25	Option Exercise	17.33	13,564	235,085	96,173	Mar 25 07:37 PM
Moore Erin	Interim PFO and PAO	Mar 24 '25	Sale	33.12	13,564	449,237	82,609	Mar 25 07:37 PM
Tracey Sacco	Affiliate	Mar 24 '25	Proposed Sale	33.00	41,500	1,369,500		Mar 24 07:20 PM
Peng Katie	Director	Mar 17 '25	Sale	34.42	1,006	34,627	30,319	Mar 19 05:00 PM
Katie Peng	Director	Mar 17 '25	Proposed Sale	34.60	4,037	139,680		Mar 17 06:50 PM
Myles Edward H	COO & CFO	Mar 10 '25	Option Exercise	13.60	112,897	1,535,083	253,637	Mar 12 07:06 PM
Myles Edward H	COO & CFO	Mar 10 '25	Sale	35.62	142,292	5,068,974	111,345	Mar 12 07:06 PM
Edward Myles	Officer	Mar 10 '25	Proposed Sale	35.00	161,890	5,666,150		Mar 10 04:15 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Option Exercise	10.19	48,308	492,186	179,594	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 19 '25	Sale	37.40	68,510	2,562,479	111,084	Feb 20 07:55 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 18 '25	Sale	36.83	4,135	152,288	131,286	Feb 20 07:55 PM
Parlavecchio Caryn	CHRO	Feb 18 '25	Sale	36.83	5,296	195,046	140,258	Feb 20 06:30 PM
Myles Edward H	COO & CFO	Feb 18 '25	Sale	36.83	7,809	287,598	140,740	Feb 20 06:18 PM
Ho Junlin	GENERAL COUNSEL	Feb 18 '25	Sale	36.83	5,742	211,472	189,295	Feb 20 05:53 PM
Backstrom Jay T.	CHIEF EXECUTIVE OFFICER	Feb 18 '25	Sale	36.83	18,372	676,622	311,991	Feb 20 05:41 PM
Mohammed Qatanani	Officer	Feb 19 '25	Proposed Sale	36.95	68,510	2,531,444		Feb 19 04:15 PM

Open in Screener

ALNY

Alnylam Pharmaceuticals Inc

Feb 13 • 04:00PM ET

314.40

+5.92 1.92 %

Healthcare • Biotechnology • USA • NASD

ALNY Alnylam Pharmaceuticals Inc daily Stock Chart

Peers: VRTX REGN BMRN BIIB IONS SRPT ARWR NTLA CRSP EDIT

| Held by: VTI VO QQQ VUG VXF VOT IBB IWP CGGR IWF

Index	NDX	P/E	139.29	EPS (ttm)	2.26	Insider Own	0.88%	Shs Outstand	132.38M	Perf Week	-4.19%
Market Cap	41.70B	Forward P/E	27.86	EPS next Y	11.28	Insider Trans	-11.96%	Shs Float	131.45M	Perf Month	-14.30%
Enterprise Value	41.76B	PEG	0.33	EPS next Q	1.07	Inst Own	100.23%	Short Float	4.02%	Perf Quarter	-30.56%
Income	313.75M	P/S	11.23	EPS this Y	200.19%	Inst Trans	2.76%	Short Ratio	3.48	Perf Half Y	-28.99%
Sales	3.71B	P/B	52.74	EPS next Y	61.33%	ROA	6.73%	Short Interest	5.28M	Perf YTD	-20.94%
Book/sh	5.96	P/C	14.34	EPS next 5Y	84.73%	ROE	73.28%	52W High	495.55 -36.56%	Perf Year	18.69%
Cash/sh	21.93	P/FCF	89.60	EPS past 3/5Y	- -	ROIC	8.98%	52W Low	205.87 52.72%	Perf 3Y	41.41%
Dividend Est.	-	EV/EBITDA	74.94	Sales past 3/5Y	52.98% 49.77%	Gross Margin	81.64%	Volatility	3.86% 3.64%	Perf 5Y	99.09%
Dividend TTM	-	EV/Sales	11.24	EPS Y/Y TTM	209.06%	Oper. Margin	13.51%	ATR (14)	13.88	Perf 10Y	427.96%
Dividend Ex-Date	-	Quick Ratio	2.71	Sales Y/Y TTM	65.19%	Profit Margin	8.45%	RSI (14)	29.82	Recom	1.69
Dividend Gr. 3/5Y	- -	Current Ratio	2.76	EPS Q/Q	310.87%	SMA20	-8.19%	Beta	0.37	Target Price	465.43
Payout	0.00%	Debt/Eq	3.76	Sales Q/Q	84.95%	SMA50	-17.13%	Rel Volume	0.92	Prev Close	308.48
Employees	2500	LT Debt/Eq	3.43	Earnings	Feb 12 BMO	SMA200	-18.80%	Avg Volume	1.52M	Price	314.40
IPO	May 28, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-29.06% -4.53%	Trades		Volume	1,390,974	Change	1.92%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$527
Jan-07-26	Resumed	Oppenheimer	Outperform	$500
Aug-04-25	Upgrade	Wolfe Research	Underperform → Peer Perform
Aug-04-25	Upgrade	Oppenheimer	Perform → Outperform	$490
Jul-30-25	Resumed	Raymond James	Outperform	$370
Jul-21-25	Initiated	Truist	Buy	$385
Mar-31-25	Initiated	Redburn Atlantic	Buy	$353
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight	$280 → $328
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy	$198 → $370
Feb-16-24	Downgrade	Goldman	Buy → Neutral	$173
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$171
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform	$208
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220
Mar-21-23	Initiated	Bernstein	Outperform	$243

Show Previous Ratings

Feb-14-26 01:21AM	Is Alnylam Pharmaceuticals (ALNY) One of the Best Upside Stocks to Invest In Right Now? (Insider Monkey)
Feb-13-26 04:30PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
10:19AM	ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down (Zacks)
Feb-12-26 04:31PM	Alnylam Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
04:06PM	Alnylam Pharmaceuticals Inc (ALNY) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
12:23PM	Loading…
12:23PM	Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor (BioPharma Dive)
10:00AM	Here's What Key Metrics Tell Us About Alnylam (ALNY) Q4 Earnings (Zacks)
09:10AM	Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates (Zacks)
08:22AM	Alnylam: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
Feb-11-26 12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
Feb-10-26 10:00AM	Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
Feb-09-26 09:15AM	Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
Feb-06-26 08:34AM	Do Options Traders Know Something About Alnylam Pharmaceuticals Stock We Don't? (Zacks)
Feb-05-26 10:00AM	Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy? (Zacks) -5.89%
09:35AM	Loading…
Jan-31-26 09:35AM	Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth (Insider Monkey)
Jan-29-26 09:55PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
04:09PM	Phillip Allen Sharp Improved Human Health With Breakthroughs (Investor's Business Daily)
02:27PM	Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy (Insider Monkey)
08:00AM	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Jan-28-26 05:04AM	Should You Buy Alnylam Pharmaceuticals Before Feb. 12? (Motley Fool)
Jan-27-26 08:38AM	Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression (Insider Monkey)
Jan-14-26 08:02AM	JPM26: 2025 a breakout year for rare disease biotechs (Clinical Trials Arena)
Jan-12-26 07:03PM	Alnylam Pharmaceuticals CEO on Development Goals, Profitability (Bloomberg) -6.87%
04:18PM	JPM Preannouncements: Why Alnylam And Sarepta Lost, But Day One Won (Investor's Business Daily)
02:42PM	Alnylam Pharmaceuticals Unveils Alnylam 2030 as Amvuttra Drives Breakout Growth at JPMorgan Conf. (MarketBeat)
01:33PM	Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale (Benzinga)
12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga)
11:15AM	Equity Indexes Recover Early Losses as Precious Metals Reach New Record Highs (Barchart)
10:18AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
06:24AM	Loading…
06:24AM	AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations (BioPharma Dive)
Jan-11-26 05:00PM	Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact (Business Wire)
Jan-09-26 09:09PM	Walmart To Join Nasdaq 100 on Jan. 20 as AstraZeneca Exits (Bloomberg) -6.87%
11:19AM	Healthcare dealmakers head to San Francisco hoping for megamergers in 2026 (Reuters)
Jan-08-26 08:00AM	Biotech Stocks' Dark Winter Is Over. What That Means For Investors. (Investor's Business Daily) -5.47%
Jan-07-26 11:02AM	Healthcare and technology stocks are driving up the Nasdaq (MarketWatch)
Jan-05-26 09:15AM	Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-30-25 11:06AM	Stocks Slip as Bond Yields Rise (Barchart)
Dec-19-25 06:18AM	Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q3 (Insider Monkey)
Dec-18-25 05:15AM	Alnylam plans $250m investment in Norton manufacturing facility, US (Pharmaceutical Technology)
Dec-17-25 08:00AM	Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics (Business Wire)
Dec-15-25 12:15PM	MicroStrategy retains place in key index despite delisting threats (TheStreet)
10:05AM	Lululemon Set to Exit Nasdaq 100 as Index Adds New Members (GuruFocus.com)
09:11AM	Western Digital stock rises after inclusion in Nasdaq-100 Index (Investing.com)
07:03AM	200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party (GuruFocus.com)
Dec-13-25 11:04AM	Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut (MarketWatch)
Dec-12-25 08:21PM	Bitcoin hoarding company Strategy remains in Nasdaq 100 (Reuters)
08:30AM	Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options (Zacks)
Dec-11-25 07:00AM	Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 (Business Wire)
Dec-07-25 02:45AM	Is Alnylam Pharmaceuticals a Millionaire Maker? (Motley Fool)
Dec-05-25 04:34PM	The S&P 500 Is Due to Rebalance on Friday. What Could Change. (Barrons.com) -6.13%
Dec-03-25 08:00AM	Alnylam Pharmaceuticals Announces Changes to Board of Directors (Business Wire)
Dec-02-25 08:11AM	These Stocks Could Join the S&P 500 in Rebalancing (Barrons.com)
08:02AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
Dec-01-25 05:09PM	These Stocks Could Join the S&P 500 in Rebalancing (Barrons.com)
03:47PM	CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing (Barrons.com)
Nov-22-25 08:00AM	S&P 500 Retailer Leads Five Resilient Stocks After Nvidia-Led Market Sell-Off (Investor's Business Daily)
Nov-20-25 01:39PM	High-Flying Biotech Stock Sets Up After 96% Pop; Profitability In Sight As Key Drug Sales Double (Investor's Business Daily)
01:35PM	Highflying Biotech Stock Sets Up After 96% Pop; Annual Profit In Sight As Key Drug Sales Double (Investor's Business Daily)
Nov-18-25 09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-13-25 09:07AM	Alnylam Pharmaceuticals (ALNY) Surged on Strong Growth and Optimistic Revenue Outlook (Insider Monkey)
03:00AM	RNAi looked doomed to fail until Alnylams science chief found a way (Pharma Voice)
Nov-11-25 05:40AM	Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money (Motley Fool)
Nov-08-25 04:57PM	New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM (Business Wire)
Nov-04-25 11:28AM	Top 20 biopharma companies Q3 2025 market cap up 4% despite headwinds (Pharmaceutical Technology)
08:00AM	Alnylam to Webcast Presentations at Upcoming November Investor Conferences (Business Wire)
Oct-31-25 10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)
08:04AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Oct-30-25 04:24PM	Alnylam Pharmaceuticals Inc (ALNY) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) -6.65%
04:19PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
01:13PM	Earnings roundup: Alnylams down day, Neurocrines head scratch and Biogens low quality win (BioPharma Dive)
10:30AM	Compared to Estimates, Alnylam (ALNY) Q3 Earnings: A Look at Key Metrics (Zacks)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
09:15AM	Alnylam Pharmaceuticals (ALNY) Q3 Earnings and Revenues Top Estimates (Zacks)
08:16AM	Alnylam: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
Oct-29-25 01:47PM	Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect (Zacks)
11:27AM	Amgen's Q3 Earnings in the Cards: Here's What to Expect (Zacks)
Oct-28-25 04:21PM	These Are The 5 Best Stocks To Buy Now Or Watch (Investor's Business Daily)
11:52AM	Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
09:15AM	Exploring Analyst Estimates for Alnylam (ALNY) Q3 Earnings, Beyond Revenue and EPS (Zacks)
Oct-27-25 12:44PM	ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? (Zacks)
10:00AM	Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-24-25 09:56AM	REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline? (Zacks)
Oct-23-25 02:54PM	Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
10:19AM	IQVIA Gears Up to Report Q3 Earnings: What's in the Cards? (Zacks)
10:00AM	Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:05AM	RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised (Zacks)
Oct-22-25 11:04AM	NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board (Zacks)
Oct-21-25 09:34AM	Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis (Zacks)
09:30AM	NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients (Zacks)
Oct-20-25 12:20PM	Why Alnylam (ALNY) Might be Well Poised for a Surge (Zacks)
Oct-18-25 09:05AM	Alnylam price target raised to $535 from $459 at Truist (TipRanks)
08:00AM	S&P 500's Walmart In Buy Zone, Leads Five Stocks Near Buy Points (Investor's Business Daily)
08:00AM	S&P 500's New AI Play? Walmart In Buy Zone, Leads Five Stocks To Watch Amid Volatile Market (Investor's Business Daily)
Oct-16-25 11:14AM	Viatris Acquires Aculys Pharma to Expand Neurology Portfolio in Japan (Zacks)
08:00AM	Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results (Business Wire)
Oct-15-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice (Zacks)
11:31AM	RCKT Stock Up as FDA Accepts Resubmitted BLA for Gene Therapy (Zacks)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garg Pushkal	EVP Chief R&D	Jan 12 '26	Sale	362.87	1,510	547,929	22,511	Jan 14 04:23 PM
Greenstreet Yvonne	Chief Executive Officer	Jan 12 '26	Sale	362.86	9,577	3,475,157	78,411	Jan 14 04:23 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Jan 12 '26	Sale	362.87	2,780	1,008,766	57,465	Jan 14 04:22 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Jan 12 '26	Sale	362.87	1,510	547,927	29,728	Jan 14 04:22 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jan 13 '26	Sale	370.33	2,290	848,065	21,264	Jan 14 04:21 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jan 12 '26	Sale	362.87	1,510	547,927	23,554	Jan 14 04:21 PM
Fitzgerald Kevin Joseph	Officer	Jan 13 '26	Proposed Sale	369.10	2,290	845,239		Jan 13 04:32 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 26 '25	Option Exercise	106.40	4,697	499,756	70,106	Dec 01 04:10 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 17 '25	Option Exercise	119.13	8,161	972,220	33,392	Nov 19 04:05 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 17 '25	Sale	452.18	12,128	5,483,990	21,264	Nov 19 04:05 PM
Fitzgerald Kevin Joseph	Officer	Nov 17 '25	Proposed Sale	449.00	12,128	5,445,472		Nov 17 04:04 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 12 '25	Option Exercise	115.94	15,650	1,814,393	81,059	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 13 '25	Option Exercise	119.13	10,000	1,191,300	75,409	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 12 '25	Sale	453.69	15,650	7,100,322	65,409	Nov 14 04:13 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 13 '25	Sale	451.27	10,000	4,512,682	65,409	Nov 14 04:13 PM
Greenstreet Yvonne	Officer	Nov 12 '25	Proposed Sale	453.10	25,650	11,621,956		Nov 12 04:03 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Oct 02 '25	Sale	452.05	3,821	1,727,284	54,052	Oct 03 05:14 PM
Greenstreet Yvonne	Chief Executive Officer	Oct 02 '25	Sale	452.05	8,924	4,034,085	65,409	Oct 03 05:14 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Oct 02 '25	Sale	452.05	1,405	635,126	27,438	Oct 03 05:14 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Oct 02 '25	Sale	452.05	2,441	1,103,451	25,231	Oct 03 05:13 PM
Garg Pushkal	EVP Chief R&D	Oct 03 '25	Sale	451.48	3,022	1,364,387	20,221	Oct 03 05:12 PM
Garg Pushkal	EVP Chief R&D	Oct 02 '25	Sale	452.05	2,937	1,327,675	23,243	Oct 03 05:12 PM
Garg Pushkal	Officer	Oct 03 '25	Proposed Sale	451.00	3,022	1,362,922		Oct 03 04:08 PM
Reitan Colleen F	Director	Sep 09 '25	Option Exercise	100.65	18,000	1,811,700	18,775	Sep 11 04:05 PM
Reitan Colleen F	Director	Sep 09 '25	Sale	467.60	18,000	8,416,730	775	Sep 11 04:05 PM
Reitan Colleen F	Director	Sep 09 '25	Proposed Sale	461.12	18,000	8,300,070		Sep 09 04:05 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Aug 29 '25	Sale	448.37	3,474	1,557,649	25,992	Sep 02 04:10 PM
Tanguler Tolga	Officer	Aug 29 '25	Proposed Sale	452.22	3,474	1,571,012		Aug 29 04:05 PM
Garg Pushkal	EVP Chief R&D	Aug 19 '25	Sale	458.41	1,455	666,987	20,221	Aug 19 05:28 PM
Garg Pushkal	EVP Chief R&D	Aug 18 '25	Sale	453.27	1,396	632,759	21,676	Aug 19 05:28 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Aug 18 '25	Sale	453.27	1,396	632,759	29,466	Aug 19 05:28 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Aug 18 '25	Sale	453.27	2,274	1,030,727	50,121	Aug 19 05:27 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 18 '25	Sale	453.27	6,979	3,163,346	56,221	Aug 19 05:27 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 18 '25	Sale	453.27	1,396	632,759	22,719	Aug 19 05:26 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Option Exercise	70.20	11,250	789,750	28,054	Aug 19 05:26 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Sale	450.00	11,250	5,062,500	16,804	Aug 19 05:26 PM
Garg Pushkal	Officer	Aug 19 '25	Proposed Sale	457.00	1,455	664,935		Aug 19 04:03 PM
BONNEY MICHAEL W	Director	Aug 18 '25	Proposed Sale	450.00	11,250	5,062,500		Aug 18 04:08 PM
Ausiello Dennis A	Director	Aug 14 '25	Option Exercise	131.34	31,448	4,130,478	32,359	Aug 15 04:05 PM
Ausiello Dennis A	Director	Aug 14 '25	Sale	436.58	31,448	13,729,536	911	Aug 15 04:05 PM
Ausiello Dennis A	Director	Aug 14 '25	Proposed Sale	433.59	31,448	13,635,538		Aug 14 04:17 PM
Greenstreet Yvonne	Chief Executive Officer	May 30 '25	Option Exercise	118.46	31,640	3,748,149	80,588	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 02 '25	Option Exercise	118.73	19,297	2,291,057	68,245	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	May 30 '25	Sale	304.39	31,640	9,630,902	48,948	Jun 03 04:10 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 02 '25	Sale	306.00	19,297	5,904,882	48,948	Jun 03 04:10 PM
Greenstreet Yvonne	Officer	Jun 02 '25	Proposed Sale	303.10	19,297	5,848,824		Jun 02 04:08 PM
Greenstreet Yvonne	Officer	May 30 '25	Proposed Sale	304.39	31,640	9,630,902		May 30 04:18 PM
SHARP PHILLIP A	Director	May 30 '25	Proposed Sale	300.00	11,250	3,375,000		May 30 04:10 PM
BONNEY MICHAEL W	Director	May 15 '25	Option Exercise	131.21	11,250	1,476,112	28,054	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Sale	277.71	11,250	3,124,217	16,804	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Proposed Sale	269.53	11,250	3,032,212		May 15 04:03 PM
Reitan Colleen F	Director	Apr 16 '25	Sale	232.86	36	8,383	0	May 12 04:05 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 24 '25	Option Exercise	42.22	5,445	229,888	25,666	Mar 25 04:10 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 24 '25	Sale	300.00	5,445	1,633,500	20,221	Mar 25 04:10 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 21 '25	Sale	285.00	4,321	1,231,485	20,221	Mar 25 04:10 PM
PYOTT DAVID E I	Director	Mar 24 '25	Option Exercise	88.95	7,440	661,788	7,576	Mar 25 04:09 PM
PYOTT DAVID E I	Director	Mar 24 '25	Sale	299.00	7,440	2,224,560	136	Mar 25 04:09 PM
PYOTT DAVID E I	Director	Mar 24 '25	Proposed Sale	299.00	7,440	2,224,560		Mar 24 04:13 PM
Garg Pushkal	Officer	Mar 24 '25	Proposed Sale	300.00	5,445	1,633,500		Mar 24 04:06 PM
Garg Pushkal	Officer	Mar 21 '25	Proposed Sale	285.00	4,321	1,231,485		Mar 21 04:03 PM
SCHULMAN AMY W	Director	Mar 13 '25	Option Exercise	131.21	2,750	360,828	11,186	Mar 14 04:16 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 03 '25	Sale	243.73	1,911	465,772	14,345	Mar 05 04:22 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 04 '25	Sale	241.15	844	203,532	13,501	Mar 05 04:22 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 03 '25	Sale	243.78	471	114,820	28,011	Mar 05 04:22 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 03 '25	Sale	243.79	1,749	426,384	25,350	Mar 05 04:21 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 04 '25	Sale	241.05	808	194,766	24,542	Mar 05 04:21 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 03 '25	Sale	243.78	1,264	308,141	47,751	Mar 05 04:21 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 03 '25	Sale	243.79	3,877	945,165	98,635	Mar 05 04:20 PM
Fitzgerald Kevin Joseph	Officer	Mar 04 '25	Proposed Sale	241.09	844	203,479		Mar 04 04:07 PM
Garg Pushkal	Officer	Mar 04 '25	Proposed Sale	241.09	808	194,801		Mar 04 04:06 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '25	Option Exercise	0.00	5,921	0	87,447	Mar 03 04:32 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 28 '25	Sale	241.69	2,900	700,894	84,547	Mar 03 04:32 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '25	Option Exercise	0.00	1,908	0	34,694	Mar 03 04:31 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 28 '25	Sale	241.70	796	192,390	33,898	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '25	Option Exercise	0.00	1,667	0	14,858	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 28 '25	Sale	241.68	513	123,983	14,345	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 27 '25	Option Exercise	0.00	1,908	0	13,897	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 28 '25	Sale	241.69	935	225,977	12,962	Mar 03 04:31 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 28 '25	Sale	241.69	496	119,878	12,385	Mar 03 04:30 PM
Garg Pushkal	Officer	Mar 03 '25	Proposed Sale	246.18	973	239,533		Mar 03 04:09 PM
Fitzgerald Kevin Joseph	Officer	Mar 03 '25	Proposed Sale	246.18	1,171	288,277		Mar 03 04:09 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 18 '25	Sale	251.56	1,440	362,243	12,881	Feb 18 04:47 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 18 '25	Sale	251.67	1,548	389,579	11,989	Feb 18 04:47 PM
Garg Pushkal	Officer	Feb 18 '25	Proposed Sale	256.95	1,548	397,759		Feb 18 04:14 PM
Fitzgerald Kevin Joseph	Officer	Feb 18 '25	Proposed Sale	256.95	1,440	370,008		Feb 18 04:13 PM

SRRK

Scholar Rock Holding Corp

ALNY

Alnylam Pharmaceuticals Inc

Upgrade your FINVIZ experience